Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Buy
58
OPHLY Quote, Financials, Valuation and Earnings
Last price:
$4.68
Seasonality move
:
4.03%
Day range:
$4.68 - $4.70
52-week range:
$3.21 - $4.74
Dividend yield:
0%
P/E ratio:
19.65x
P/S ratio:
1.58x
P/B ratio:
1.18x
Volume:
12K
Avg. volume:
34.1K
1-year change:
24.73%
Market cap:
$6.5B
Revenue:
$3.2B
EPS (TTM):
$0.23
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
OPHLY
Ono Pharmaceutical Co., Ltd.
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$7.8B | -- | 3.35% | -- | $17.76 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
OPHLY
Ono Pharmaceutical Co., Ltd.
|
$4.59 | -- | $6.5B | 19.65x | $0.09 | 0% | 1.58x |
|
HLOSF
Healios KK
|
$2.31 | -- | $266.6M | -- | $0.00 | 0% | 362.71x |
|
PPTDF
PeptiDream Inc.
|
$12.19 | -- | $1.6B | 13.79x | $0.00 | 0% | 13.13x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.50 | -- | $497.7M | -- | $0.00 | 0% | 2.57x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$14.33 | $17.76 | $45.3B | 181.85x | $0.32 | 4.61% | 1.54x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
OPHLY
Ono Pharmaceutical Co., Ltd.
|
13.92% | -0.186 | 16.45% | 2.29x |
|
HLOSF
Healios KK
|
47.23% | -1.205 | 3.71% | 1.23x |
|
PPTDF
PeptiDream Inc.
|
25.86% | 0.045 | 8.66% | 4.05x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
49.02% | 1.721 | 73.82% | 2.21x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
39.45% | -0.563 | 68.02% | 0.64x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
OPHLY
Ono Pharmaceutical Co., Ltd.
|
$641.7M | $202M | 5.18% | 6.13% | 22.98% | $340.4M |
|
HLOSF
Healios KK
|
-$637.4K | -$5.2M | -86.08% | -194.37% | -4022.21% | -$5.3M |
|
PPTDF
PeptiDream Inc.
|
$11.3M | -$9.7M | -7.71% | -10.42% | -33.1% | -$12.5M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$27.7M | -$23.7M | -4.62% | -9.2% | -51.66% | -$20.9M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$3.6B | $763.2M | 0.33% | 0.55% | 10.11% | $2B |
Ono Pharmaceutical Co., Ltd. vs. Competitors
-
Which has Higher Returns OPHLY or HLOSF?
Healios KK has a net margin of 17.25% compared to Ono Pharmaceutical Co., Ltd.'s net margin of -9751.87%. Ono Pharmaceutical Co., Ltd.'s return on equity of 6.13% beat Healios KK's return on equity of -194.37%.
Company Gross Margin Earnings Per Share Invested Capital OPHLYOno Pharmaceutical Co., Ltd.73.02% $0.11 $6.4B HLOSFHealios KK-494.88% $0.03 $37.8M -
What do Analysts Say About OPHLY or HLOSF?
Ono Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Ono Pharmaceutical Co., Ltd. has higher upside potential than Healios KK, analysts believe Ono Pharmaceutical Co., Ltd. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings OPHLYOno Pharmaceutical Co., Ltd.0 0 0 HLOSFHealios KK0 0 0 -
Is OPHLY or HLOSF More Risky?
Ono Pharmaceutical Co., Ltd. has a beta of 0.302, which suggesting that the stock is 69.808% less volatile than S&P 500. In comparison Healios KK has a beta of 0.210, suggesting its less volatile than the S&P 500 by 78.954%.
-
Which is a Better Dividend Stock OPHLY or HLOSF?
Ono Pharmaceutical Co., Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ono Pharmaceutical Co., Ltd. pays 50.74% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Ono Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios OPHLY or HLOSF?
Ono Pharmaceutical Co., Ltd. quarterly revenues are $878.8M, which are larger than Healios KK quarterly revenues of $128.8K. Ono Pharmaceutical Co., Ltd.'s net income of $151.6M is higher than Healios KK's net income of $3.8M. Notably, Ono Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 19.65x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ono Pharmaceutical Co., Ltd. is 1.58x versus 362.71x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OPHLYOno Pharmaceutical Co., Ltd.1.58x 19.65x $878.8M $151.6M HLOSFHealios KK362.71x -- $128.8K $3.8M
-
Which has Higher Returns OPHLY or PPTDF?
PeptiDream Inc. has a net margin of 17.25% compared to Ono Pharmaceutical Co., Ltd.'s net margin of -25.38%. Ono Pharmaceutical Co., Ltd.'s return on equity of 6.13% beat PeptiDream Inc.'s return on equity of -10.42%.
Company Gross Margin Earnings Per Share Invested Capital OPHLYOno Pharmaceutical Co., Ltd.73.02% $0.11 $6.4B PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M -
What do Analysts Say About OPHLY or PPTDF?
Ono Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Ono Pharmaceutical Co., Ltd. has higher upside potential than PeptiDream Inc., analysts believe Ono Pharmaceutical Co., Ltd. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings OPHLYOno Pharmaceutical Co., Ltd.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is OPHLY or PPTDF More Risky?
Ono Pharmaceutical Co., Ltd. has a beta of 0.302, which suggesting that the stock is 69.808% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.146%.
-
Which is a Better Dividend Stock OPHLY or PPTDF?
Ono Pharmaceutical Co., Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ono Pharmaceutical Co., Ltd. pays 50.74% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend. Ono Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios OPHLY or PPTDF?
Ono Pharmaceutical Co., Ltd. quarterly revenues are $878.8M, which are larger than PeptiDream Inc. quarterly revenues of $29.3M. Ono Pharmaceutical Co., Ltd.'s net income of $151.6M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, Ono Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 19.65x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ono Pharmaceutical Co., Ltd. is 1.58x versus 13.13x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OPHLYOno Pharmaceutical Co., Ltd.1.58x 19.65x $878.8M $151.6M PPTDFPeptiDream Inc.13.13x 13.79x $29.3M -$7.4M
-
Which has Higher Returns OPHLY or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of 17.25% compared to Ono Pharmaceutical Co., Ltd.'s net margin of -24.76%. Ono Pharmaceutical Co., Ltd.'s return on equity of 6.13% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.
Company Gross Margin Earnings Per Share Invested Capital OPHLYOno Pharmaceutical Co., Ltd.73.02% $0.11 $6.4B SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M -
What do Analysts Say About OPHLY or SOLTF?
Ono Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Ono Pharmaceutical Co., Ltd. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Ono Pharmaceutical Co., Ltd. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings OPHLYOno Pharmaceutical Co., Ltd.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is OPHLY or SOLTF More Risky?
Ono Pharmaceutical Co., Ltd. has a beta of 0.302, which suggesting that the stock is 69.808% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.029, suggesting its less volatile than the S&P 500 by 97.149%.
-
Which is a Better Dividend Stock OPHLY or SOLTF?
Ono Pharmaceutical Co., Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ono Pharmaceutical Co., Ltd. pays 50.74% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend. Ono Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios OPHLY or SOLTF?
Ono Pharmaceutical Co., Ltd. quarterly revenues are $878.8M, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. Ono Pharmaceutical Co., Ltd.'s net income of $151.6M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, Ono Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 19.65x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ono Pharmaceutical Co., Ltd. is 1.58x versus 2.57x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OPHLYOno Pharmaceutical Co., Ltd.1.58x 19.65x $878.8M $151.6M SOLTFNxera Pharma Co., Ltd.2.57x -- $45.8M -$11.3M
-
Which has Higher Returns OPHLY or STMM?
Stemcell Holdings, Inc. has a net margin of 17.25% compared to Ono Pharmaceutical Co., Ltd.'s net margin of --. Ono Pharmaceutical Co., Ltd.'s return on equity of 6.13% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OPHLYOno Pharmaceutical Co., Ltd.73.02% $0.11 $6.4B STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About OPHLY or STMM?
Ono Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Ono Pharmaceutical Co., Ltd. has higher upside potential than Stemcell Holdings, Inc., analysts believe Ono Pharmaceutical Co., Ltd. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OPHLYOno Pharmaceutical Co., Ltd.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is OPHLY or STMM More Risky?
Ono Pharmaceutical Co., Ltd. has a beta of 0.302, which suggesting that the stock is 69.808% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock OPHLY or STMM?
Ono Pharmaceutical Co., Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ono Pharmaceutical Co., Ltd. pays 50.74% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend. Ono Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios OPHLY or STMM?
Ono Pharmaceutical Co., Ltd. quarterly revenues are $878.8M, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Ono Pharmaceutical Co., Ltd.'s net income of $151.6M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Ono Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 19.65x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ono Pharmaceutical Co., Ltd. is 1.58x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OPHLYOno Pharmaceutical Co., Ltd.1.58x 19.65x $878.8M $151.6M STMMStemcell Holdings, Inc.0.17x -- -- --
-
Which has Higher Returns OPHLY or TAK?
Takeda Pharmaceutical Co., Ltd. has a net margin of 17.25% compared to Ono Pharmaceutical Co., Ltd.'s net margin of -1.05%. Ono Pharmaceutical Co., Ltd.'s return on equity of 6.13% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.
Company Gross Margin Earnings Per Share Invested Capital OPHLYOno Pharmaceutical Co., Ltd.73.02% $0.11 $6.4B TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B -
What do Analysts Say About OPHLY or TAK?
Ono Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.76 which suggests that it could grow by 23.73%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Ono Pharmaceutical Co., Ltd., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Ono Pharmaceutical Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings OPHLYOno Pharmaceutical Co., Ltd.0 0 0 TAKTakeda Pharmaceutical Co., Ltd.3 0 0 -
Is OPHLY or TAK More Risky?
Ono Pharmaceutical Co., Ltd. has a beta of 0.302, which suggesting that the stock is 69.808% less volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, suggesting its less volatile than the S&P 500 by 96.811%.
-
Which is a Better Dividend Stock OPHLY or TAK?
Ono Pharmaceutical Co., Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.61% to investors and pays a quarterly dividend of $0.32 per share. Ono Pharmaceutical Co., Ltd. pays 50.74% of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend. Ono Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.
-
Which has Better Financial Ratios OPHLY or TAK?
Ono Pharmaceutical Co., Ltd. quarterly revenues are $878.8M, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. Ono Pharmaceutical Co., Ltd.'s net income of $151.6M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, Ono Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 19.65x while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 181.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ono Pharmaceutical Co., Ltd. is 1.58x versus 1.54x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OPHLYOno Pharmaceutical Co., Ltd.1.58x 19.65x $878.8M $151.6M TAKTakeda Pharmaceutical Co., Ltd.1.54x 181.85x $7.5B -$79.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
73
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 39x
Alerts
Buy
80
FEIM alert for Dec 16
Frequency Electronics, Inc. [FEIM] is down 3.51% over the past day.
Buy
57
MOD alert for Dec 15
Modine Manufacturing Co. [MOD] is up 1.79% over the past day.
Sell
42
OKLO alert for Dec 15
Oklo, Inc. [OKLO] is down 5.81% over the past day.
